Market Cap 419.39M
Revenue (ttm) 0.00
Net Income (ttm) -243.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 625,000
Avg Vol 1,381,850
Day's Range N/A - N/A
Shares Out 167.09M
Stochastic %K 1%
Beta 2.49
Analysts Sell
Price Target $9.14

Company Profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associa...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 760 0900
Address:
490 Arsenal Way, Suite 200, Watertown, United States
Kaltycoon
Kaltycoon Mar. 19 at 2:02 PM
$NMRA trend is my friend - reload zone around 2.40-2.50
0 · Reply
AlphaDeskWealth
AlphaDeskWealth Mar. 18 at 9:07 PM
$NMRA Some derisking across the board due to 1. FOMC, Biotech's are sensitive to higher for longer interest rates and leads to future value getting discounted more. 2. Inflated oil prices, fearing stagflation liquidity gets sucked out of risky assets like biotech and moves to more defensive sectors 3. Broad market sell-off, biotech's are notorious for 2x-3x beta in market downshifts Low volume on the past 5 days with the 30 March closing in there is certainly some short term traders moving to the sidelines. With relative volume hitting 0.4x and no acceleration in selling could create a supply shortage on positive news and fueling the next catalyst. Trading around the 50MA (2.53-2.60) will also attract interest from funds that have not scaled in their complete positions. Including dark pool activity spiking clearly around the 2.64-2.66 range. With no new information or change in any dynamics the current price is just a discount on the 3.50 level.
1 · Reply
Mr_GA
Mr_GA Mar. 18 at 4:58 AM
$NMRA https://www.msn.com/en-us/money/general/glp-1-drugs-linked-to-higher-fracture-risk-osteoporosis-and-gout-new-studies-suggest/ar-AA1XJzta
1 · Reply
InvestorCG
InvestorCG Mar. 17 at 1:58 PM
$NMRA not much to say at this moment. Extended silence plus a convertible overhang that is clearly selling = downward share price.
2 · Reply
Mr_GA
Mr_GA Mar. 16 at 5:24 PM
$NMRA https://childrenshealthdefense.org/defender/novo-nordisk-ozempic-wegovy-fda-warning-letter-fail-report-deaths-side-effects/
1 · Reply
SizeableVirus
SizeableVirus Mar. 16 at 2:14 PM
$NMRA Ready for another day of losing money? 😆
3 · Reply
InvestorCG
InvestorCG Mar. 16 at 1:41 PM
$NMRA https://finance.yahoo.com/news/neumora-therapeutics-report-fourth-quarter-110000186.html
0 · Reply
InvestorCG
InvestorCG Mar. 13 at 3:47 PM
$NMRA Last time K2 was dumping, if I recall, our PR went silent. Same thing here it appears. When we getting the Q? Would have been nice to have presented at Leerink too to keep interest up so we can absorb the overhang quicker.
0 · Reply
Jfredwing1
Jfredwing1 Mar. 13 at 3:45 PM
$NMRA The trading swings on this stock are crazy.
0 · Reply
Keystone1
Keystone1 Mar. 12 at 2:41 PM
$NMRA Just picked up another 10,000 shares on the drop!
0 · Reply
Latest News on NMRA
Neumora Therapeutics to Host Virtual R&D Day on October 27

Oct 1, 2025, 7:00 AM EDT - 6 months ago

Neumora Therapeutics to Host Virtual R&D Day on October 27


Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript

May 12, 2025, 7:18 PM EDT - 11 months ago

Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript


Kaltycoon
Kaltycoon Mar. 19 at 2:02 PM
$NMRA trend is my friend - reload zone around 2.40-2.50
0 · Reply
AlphaDeskWealth
AlphaDeskWealth Mar. 18 at 9:07 PM
$NMRA Some derisking across the board due to 1. FOMC, Biotech's are sensitive to higher for longer interest rates and leads to future value getting discounted more. 2. Inflated oil prices, fearing stagflation liquidity gets sucked out of risky assets like biotech and moves to more defensive sectors 3. Broad market sell-off, biotech's are notorious for 2x-3x beta in market downshifts Low volume on the past 5 days with the 30 March closing in there is certainly some short term traders moving to the sidelines. With relative volume hitting 0.4x and no acceleration in selling could create a supply shortage on positive news and fueling the next catalyst. Trading around the 50MA (2.53-2.60) will also attract interest from funds that have not scaled in their complete positions. Including dark pool activity spiking clearly around the 2.64-2.66 range. With no new information or change in any dynamics the current price is just a discount on the 3.50 level.
1 · Reply
Mr_GA
Mr_GA Mar. 18 at 4:58 AM
$NMRA https://www.msn.com/en-us/money/general/glp-1-drugs-linked-to-higher-fracture-risk-osteoporosis-and-gout-new-studies-suggest/ar-AA1XJzta
1 · Reply
InvestorCG
InvestorCG Mar. 17 at 1:58 PM
$NMRA not much to say at this moment. Extended silence plus a convertible overhang that is clearly selling = downward share price.
2 · Reply
Mr_GA
Mr_GA Mar. 16 at 5:24 PM
$NMRA https://childrenshealthdefense.org/defender/novo-nordisk-ozempic-wegovy-fda-warning-letter-fail-report-deaths-side-effects/
1 · Reply
SizeableVirus
SizeableVirus Mar. 16 at 2:14 PM
$NMRA Ready for another day of losing money? 😆
3 · Reply
InvestorCG
InvestorCG Mar. 16 at 1:41 PM
$NMRA https://finance.yahoo.com/news/neumora-therapeutics-report-fourth-quarter-110000186.html
0 · Reply
InvestorCG
InvestorCG Mar. 13 at 3:47 PM
$NMRA Last time K2 was dumping, if I recall, our PR went silent. Same thing here it appears. When we getting the Q? Would have been nice to have presented at Leerink too to keep interest up so we can absorb the overhang quicker.
0 · Reply
Jfredwing1
Jfredwing1 Mar. 13 at 3:45 PM
$NMRA The trading swings on this stock are crazy.
0 · Reply
Keystone1
Keystone1 Mar. 12 at 2:41 PM
$NMRA Just picked up another 10,000 shares on the drop!
0 · Reply
Keystone1
Keystone1 Mar. 12 at 12:23 PM
$NMRA Up again premarket! I’m hoping we have a coiled spring ready to launch.
0 · Reply
Mr_GA
Mr_GA Mar. 12 at 3:00 AM
$NMRA https://finance.yahoo.com/news/neumora-therapeutics-nmra-positioned-capitalize-001139243.html
0 · Reply
AlphaDeskWealth
AlphaDeskWealth Mar. 12 at 12:14 AM
$NMRA @InvestorCG If JPM can add nmra to their Positive Catalyst Watch it can be the start of the rerating after the readout. When the binary risk from the trial is removed by positive data they will likely argue that the execution risk they cited in their September 2025 Sell note has been resolved. Paired with the NMRA 511 data not being part of the original sell thesis. We could likely see a jump from Underweight to Overweight and a large increase in price target. The rating will trigger algorithmic buy alerts for every institutional desk that uses JPM’s data feed leading to buying pressure. Getting added back to the russell 2000 will also provide buying pressure is we can sustain the current price levels by end April through to June, this will force passive funds to buy around 4m-6m worth of stock. The potential for a exponential move is building on multiple probabilities. Would be interesting to see if there's any offers around the same time.
2 · Reply
AlphaDeskWealth
AlphaDeskWealth Mar. 11 at 9:28 PM
$NMRA @InvestorCG @Keystone1 K2HV converted $2.5 million of their term loan principal into 2,849,327 shares at a fixed price of $0.8774, Under the terms of their $12.5 million conversion right, K2HV still holds the right to convert approximately $10 million of additional principal into equity. At the current conversion price, this represents the potential for roughly 11.4 million additional shares to enter the float. Considering the risk of 11 million shares tanking the stock price we would probably see extended periods of offloading unless they can find a larger institution to do a large cross without effecting the price. This most likely is just strategic asset management by rebalancing their capital to ensure funding for other and future projects. If the concern we're the upcoming readout we would see large 10% blocks to derisk well ahead of any announcement. The more they convert the better for current accumulating funds by keeping prices subdued and creating pressure for the readouts.
2 · Reply
InvestorCG
InvestorCG Mar. 11 at 1:59 PM
$NMRA can someone here call NMRA IR and ask why we are not presenting at Leerink today(or if we are, why it was not PR'd)? They won't answer me because sometimes I ask the difficult questions :-P
0 · Reply
InvestorCG
InvestorCG Mar. 11 at 1:52 PM
$NMRA looks like K2 is becoming a bit more aggressive over the past week.
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 10 at 7:53 PM
$NMRA RSI: 36.89, MACD: 0.1805 Vol: 0.21, MA20: 3.28, MA50: 2.52 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SizeableVirus
SizeableVirus Mar. 10 at 7:50 PM
$NMRA The level of price manipulation in this stock is a joke, haha
0 · Reply
InvestorCG
InvestorCG Mar. 10 at 7:45 PM
$NMRA need alot more volume to flush out this turd overhang. If they are about 20% of daily volume (probably closer to 15%) then we have more to go.
0 · Reply
InvestorCG
InvestorCG Mar. 10 at 3:37 PM
$NMRA not surprised how thin this trades to upside when K2 nowhere to be found. See if this stays this way. I'm surprised we haven't seen a PR about Q or Leerink, if we are presenting.
1 · Reply
Keystone1
Keystone1 Mar. 10 at 2:39 PM
$NMRA Knocking on 3.50 hello 4$
0 · Reply
cheating_stock_investor
cheating_stock_investor Mar. 10 at 2:26 PM
$NMRA cross through 4 like we did 3s shortly
0 · Reply